Realizing the Full Potential of Harvard’s Promising Life Science Research
Harvard faculty researchers are at the forefront of life science and biomedical innovation.
However, propelling early-stage research beyond the lab to realize its promise for patients and society is a major challenge. The Blavatnik Biomedical Accelerator at Harvard University provides essential gap funding, development support, and business expertise to help faculty investigators achieve the full potential of their work.
The Blavatnik Biomedical Accelerator provides principal investigators employed by Harvard University with:
- Financial support to fuel translational research, proof-of-concept, and development of nascent technologies—funding that is difficult to obtain from traditional sources
- Commercial expertise to help faculty investigators successfully navigate the transition of their technologies from the academic lab to the commercial sphere
- Pathways to partnership, helping generate licensing opportunities, facilitate startup formation and investment, and realizing other commercialization avenues for novel technologies
Proposals are welcomed from Harvard principal investigators with early-stage research in a range of life science areas, including therapeutics, diagnostics, drug delivery technologies, medical devices/instruments, and enabling technologies for drug discovery.
View the current Request for Proposals, issued August 3, 2018.
The Accelerator has been indispensable in helping me in the translation process for a number of my technologies, especially by providing support for medicinal chemistry, which was essential to design and make compounds to advance my work.
Junying Yuan, PhD
Professor of Cell Biology, Harvard Medical School